R&D News | pharmaphorum

News

Boehringer says R&D pipeline is the best in its long history

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that

News

‘Stiffness’ of cells could give early warning of cancer

A new technology developed in the UK could make it possible to detect cancer at an early stage, long before the formation of a lump, by investigating the stiffness of indi

News

Regeneron launches $500m venture capital arm

Regeneron has formed a corporate venture capital unit with $100 million a year to invest over the next five years in “biopharmaceutical, healthcare, and health technology”

News

Study warns of chronic kidney disease timebomb

Up to one in six people in eight industrialised nations could be suffering from chronic kidney disease (CKD) by 2032, with dire consequences for “patients, [the] planet, a

News

After ph3 win, Roche eyes earlier use of Columvi in DLBCL

Roche’s CD20xCD3 bispecific antibody Columvi has improved survival when used as a second-line therapy for diffuse large B-cell lymphoma (DLBCL) in a phase 3 trial, setting

News

BioMarin’s Voxzogo shows promise in hypochondroplasia

BioMarin’s Voxzogo has been shown to increase growth rates in children with hypochondroplasia, a genetic cause of very short stature, in a phase 2 trial.

Boehringer says R&D pipeline is the best in its long history

‘Stiffness’ of cells could give early warning of cancer

Regeneron launches $500m venture capital arm

Study warns of chronic kidney disease timebomb

After ph3 win, Roche eyes earlier use of Columvi in DLBCL

BioMarin’s Voxzogo shows promise in hypochondroplasia

Novo Nordisk preps filings for sickle cell drug etavopivat

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks